miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation

Kenichi Hirabayashi1,2,*, Masaki Miyazawa3, Yumi Takanashi2, Masashi Morimachi4, Aya Kawanishi3, Tsubasa Saika5, Toshio Nakagohri6 & Naoya Nakamura2

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant tumor. Several upregulated and downregulated microRNAs (miRNAs) are associated with invasiveness, tumorigenesis, and prognosis of PDAC. Herein, using in situ hybridization, we evaluated miR-4653-3p expression and pancreatic intraepithelial neoplasia (PanIN) and the association between miR-4653-3p expression and clinicopathological factors in PDAC patients. The miR-4653-3p target was also identified. Ninety PDAC cases, including 30 each with normal pancreatic ducts, low-grade PanINs, and high-grade PanINs, were evaluated. miR-4653-3p expression increased in the order—normal pancreatic duct, low-grade PanIN, high-grade PanIN, and PDAC—with no expression detected in normal pancreatic duct. High expression significantly correlated with advanced pathological T stage, lymph node metastasis, advanced Union for International Cancer Control stage, perineural invasion, venous involvement, and shorter overall and disease-specific survival. Homeodomain Interacting Protein Kinase 2 (HIPK2) was identified as a miR-4653-3p target based on mRNA microarray analysis and database screening. In MIA PaCa-2 cells, miR-4653-3p significantly downregulated HIPK2 expression. HIPK2 expression, unlike that of miR-4653-3p, decreased in the order—normal pancreatic duct, low-grade PanIN, high-grade PanIN, and PDAC—with no expression detected in normal pancreatic duct. High HIPK2 expression was associated with shorter overall disease-specific survival in PDAC patients. Thus, miR-4653-3p associates with tumorigenesis and worse prognosis, partly by reducing HIPK2 expression.

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant tumor. It has few specific symptoms, is usually diagnosed at an advanced stage, and only approximately 10% of cases are operable1. Pancreatic intraepithelial neoplasia (PanIN) is a microscopically flat or papillary intraductal lesion, considered the main precursor lesion of invasive ductal carcinoma2. PanIN was initially classified into three grades, PanIN-1 (PanIN-1A and 1B), PanIN-2, and PanIN-33, but has since been reclassified as either low-grade (PanIN-1 and PanIN-2) or high-grade (PanIN-3) PanIN2,4.

MicroRNAs (miRNAs) are endogenous, non-coding RNA molecules, typically 18–22 nucleotides in length, that play important roles in biological processes, such as apoptosis, metabolism, cell growth, and differentiation, by negatively modulating gene expression at the post-transcriptional level5,6. Furthermore, the role of miRNAs as oncogenic or tumor suppressors has been reported in various cancers, including pancreatic cancer5. Multiple miRNAs are involved in PDAC, including two types that are involved in PDAC development7. Some miRNAs are

1Department of Diagnostic Pathology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. 2Department of Pathology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. 3Department of Health Management, Tokai University, Hiratsuka, Kanagawa 259-1292, Japan. 4Department of Gastroenterology and Hepatology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. 5Division of Diagnostic Pathology, Tokai University Hospital, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. 6Department of Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. 7email: hiraken@med.u-toyama.ac.jp
miR-4653-3p is a mature miRNA. Its upregulation has been reported in xanthohumol-treated glioblastoma cells, in glioma stem cells compared with that in neural stem cells, and in breast cancer MCF-7 cells overexpressing the HER-2 gene. Moreover, miR-4653-3p downregulation has been reported in paclitaxel-resistant nasopharyngeal carcinoma CNE-1/Taxol cells compared with that in parental CNE-1 cells and in recurrence/metastatic lesions compared with that in primary lesions in patients with breast cancer who relapsed after tamoxifen treatment. However, to the best of our knowledge, the expression of miR-4653-3p in PDAC patients has not been investigated, as of date.

In this study, we investigated the association between miR-4653-3p expression, as determined via in situ hybridization (ISH), and clinicopathological factors and assessed the impact of miR-4653-3p expression on survival outcomes in patients with PDAC. Furthermore, we identified the target of miR-4653-3p, which is associated with survival outcomes, and found that miR-4653-3p downregulates HIPK2 and that it may be associated with metastasis, shorter survival, and tumorigenesis in PDAC.

**Results**

**Clinicopathological features.** The mean age of the 90 patients with PDAC (43 males, 47.8%; 47 females, 52.2%) was 68 years (43–86 years) (Table 1). The mean tumor size was 37 mm (7–110 mm) in diameter. Peripheral nerve invasion, lymphatic involvement, and venous involvement were found in 81 (90%), 79 (87.8%), and 84 (93.3%) cases, respectively. G1 (well-differentiated adenocarcinoma), G2 (moderately differentiated adenocarcinoma), and G3 (poorly differentiated adenocarcinoma) tumors were diagnosed in 44 (48.9%), 44 (48.9%), and 84 (93.3%) cases, respectively. G1 (well-differentiated adenocarcinoma), G2 (moderately differentiated adenocarcinoma), and G3 (poorly differentiated adenocarcinoma) tumors were diagnosed in 44 (48.9%), 44 (48.9%), and 84 (93.3%) cases, respectively. G1 (well-differentiated adenocarcinoma), G2 (moderately differentiated adenocarcinoma), and G3 (poorly differentiated adenocarcinoma) tumors were diagnosed in 44 (48.9%), 44 (48.9%), and 84 (93.3%) cases, respectively. G1 (well-differentiated adenocarcinoma), G2 (moderately differentiated adenocarcinoma), and G3 (poorly differentiated adenocarcinoma) tumors were diagnosed in 44 (48.9%), 44 (48.9%), and 84 (93.3%) cases, respectively.

**Analysis of miR-4653-3p expression using ISH and its correlation with clinicopathological factors.** miR-4653-3p was diffusely and strongly expressed in the cytoplasm of acinar cells in normal pancreatic tissues. Islet cells expressed either little or no miR-4653-3p (Fig. 1a). However, normal pancreatic ducts did not express miR-4653-3p (H-score 0, n = 30) (Figs. 1a and 2a). The mean H-score was 67.7 (0–280) in low-grade PanIN, 143.3 (5–300) in high-grade PanIN, and 127.9 (0–300) in PDAC (Figs. 1b–d and 2a). There were significant differences in the mean miR-4653-3p H-scores between PDAC and normal pancreatic duct (p < 0.001), PDAC and low-grade PanIN (p < 0.001), high-grade PanIN and normal pancreatic duct (p < 0.001), high-grade PanIN and low-grade PanIN (p = 0.001), and low-grade PanIN and normal pancreatic duct (p < 0.001). However, there was no significant difference in the mean miR-4653-3p H-scores between high-grade PanIN and PDAC (p = 0.397). In PDAC, 32 cases (35.6%) had high miR-4653-3p expression while 58 cases (64.4%) had high miR-4653-3p expression. High miR-4653-3p expression was associated with pT3 (tumor size ≥ 4 cm; p = 0.003), pN1-2 (p = 0.017), perineural invasion (p = 0.048), venous involvement (p = 0.02), and stages IIA–IV (p < 0.001). There were no correlations between miR-4653-3p expression and age, sex, pM-factor, lymphatic involvement, or tumor grade (Table 1). High miR-4653-3p expression was associated with shorter overall and disease-specific survival in the log-rank test. The median overall survival was 29 months (95% CI: 3.75–54.25) for patients with low miR-4653-3p expression and 23 months (95% CI: 14.522–31.478) for patients with high miR-4653-3p expression (log-rank test: p = 0.046, Fig. 3a). The median disease-specific survival was 51 months (95% CI: 25.176–76.824) for patients with low miR-4653-3p expression and 23 months (95% CI: 14.522–31.478) for patients with high miR-4653-3p expression (log-rank test: p = 0.019, Fig. 3c). However, multivariate analysis showed that miR-4653-3p was not an independent prognostic factor (Supplementary Table 1a). There was no significant difference in progression-free survival between low and high miR-4653-3p expression groups (log-rank test: p = 0.083, Fig. 3e).

**mRNA microarray.** To identify the target of miR-4653-3p, we performed mRNA microarray analysis and compared mRNA expression between MIA PaCa-2 cells transfected with miR-4653-3p mimic and negative control cells. mRNA microarray analysis revealed that 517 mRNAs were significantly downregulated, and 635 mRNAs were significantly upregulated in MIA PaCa-2 cells transfected with miR-4653-3p mimic compared with that in negative control cells (|fold change| > 2.0, p < 0.05) (Supplementary Table 2).

**Screening miR-4653-3p target molecules.** TargetScan v.7.2 and Human Protein Atlas v. 19.3 were used to screen for targets of miR-4653-3p. First, we identified 163 out of the 517 mRNAs downregulated in miR-4653-3p-transfected cells by microarray analysis and listed them as predicted targets of miR-4653-3p in TargetScan. Next, among these 163 mRNAs, we selected 13 mRNAs (ADAL, ADCK1, BCORL1, GNPTG, HIPK2, LRRN3, NCOA1, NKAIN1,
PLAGL2, POMGNT1, PXK, TUBD1, and ZKSCAN1) showing significantly unfavorable prognosis with low mRNA expression in pancreatic cancer, which were expressed in normal pancreatic ducts in the Human Protein Atlas. In the above screening, we focused on HIPK2 because low HIPK2 expression is associated with poor prognosis in pancreatic cancer, and HIPK2 is associated with tumor suppressor p53, one of the major molecules underlying PDAC tumorigenesis.

Luciferase reporter assay, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and western blot analysis. To determine whether miR-4653-3p could downregulate HIPK2 expression, we performed real-time RT-qPCR, western blot, and luciferase assays. The miR-4653-3p mimic downregulated luciferase activity to 50.0% and 43.2% at miR-4653-3p target position 929–935 (target 1) and 7620–7627 (target 3) compared with that in the negative control (NC) mimic, but not at target position 5947–5953 (target 2; \( p = 0.500 \)). Means ± (standard deviation) SD from four independent experiments are shown in Fig. 4a. In real-time RT-qPCR, HIPK2 mRNA expression in PDAC cells transfected with miR-4653-3p mimic was downregulated to 16.6% compared with that in NC cells (\( p < 0.001 \)). In contrast, there was no significant difference in the expression of HIPK2 mRNA between PDAC cells transfected with miR-4653-3p inhibitor and NC cells (\( p = 0.683 \); Fig. 4b). In the western blot assay, the expression of HIPK2 in PDAC cells transfected with miR-4653-3p mimic was downregulated to 17.3% compared with that in NC cells (\( p < 0.001 \)). In contrast, there was no significant difference in the expression of HIPK2 mRNA between PDAC cells transfected with miR-4653-3p inhibitor and NC cells (\( p = 0.935 \); Fig. 4c, d). Taken together, these results show that HIPK2 is the target of miR-4653-3p and that miR-4653-3p downregulates HIPK2 in PDAC cell lines.

| Total number of cases | miR4653-3p expression | \( p \) value |
|-----------------------|-----------------------|--------------|
|                       | Low \((n = 32)\) | High \((n = 58)\) |
| Age                   | n (%) | n (%) | |
| ≤ 65 years \((n = 32)\) | 13 (40.6) | 19 (59.4) | 0.456 |
| > 65 years \((n = 58)\) | 19 (32.8) | 39 (67.2) |   |
| Gender                | 12 (27.9) | 31 (72.1) | 0.147 |
| Male \((n = 43)\)     | 20 (42.6) | 27 (57.4) |   |
| Female \((n = 47)\)   | 11 (23.4) | 36 (76.6) |   |
| Primary tumor (pT)    | 28 (45.9) | 33 (54.1) | 0.003 |
| pT1-pT2 \((n = 61)\)  | 4 (13.8) | 25 (86.2) |   |
| pT3 \((n = 29)\)      | 12 (41.4) | 17 (58.6) |   |
| Regional lymph node metastasis (pN) | 20 (48.8) | 21 (51.2) | 0.017 |
| pN0 \((n = 41)\)      | 12 (24.5) | 37 (75.5) |   |
| pN1-2 \((n = 49)\)    | 11 (30.8) | 28 (69.2) |   |
| Distant metastasis (pM) | 31 (36) | 55 (64) | 0.552 |
| pM0 \((n = 86)\)      | 1 (25) | 3 (75) |   |
| pM1 \((n = 4)\)       | 1 (25) | 3 (75) |   |
| Stage                 | 19 (59.4) | 13 (40.6) | < 0.001 |
| Stage IA-IB \((n = 32)\) | 1 (6.3) | 16 (93.7) |   |
| Stage IIA-IV \((n = 58)\) | 13 (22.4) | 45 (77.6) |   |
| Perineural invasion   | 6 (66.7) | 3 (33.3) | 0.048 |
| Yes \((n = 81)\)      | 26 (32.1) | 55 (67.9) |   |
| Lymphatic involvement | 6 (54.5) | 5 (45.5) | 0.143 |
| No \((n = 11)\)       | 26 (32.9) | 53 (67.1) |   |
| Venous involvement    | 5 (83.3) | 1 (16.7) | 0.02 |
| Yes \((n = 84)\)      | 27 (32.1) | 57 (67.9) |   |
| Tumor grade           | 15 (34.1) | 29 (65.9) | 0.776 |
| G1 \((n = 44)\)       | 17 (37) | 29 (63) |   |

Table 1. miR-4653-3p expression and clinicopathological parameters.
HIPK2 immunohistochemistry. Next, immunohistochemistry was performed to detect HIPK2. HIPK2 was expressed in the nuclei of normal pancreatic ducts, normal acinar cells, normal islet cells, PanIN cells, and PDAC cells (Fig. 5). The mean H-score for HIPK2 was 282.3 (240–300) in patients with normal pancreatic ducts, 267 (150–300) in patients with low-grade PanIN, 240.5 (100–300) in patients with high-grade PanIN, and 223.1 (100–300) in patients with PDAC (Fig. 2b). Significant differences were observed in the mean HIPK2 H-scores between normal pancreatic duct and PDAC (p < 0.001), low-grade PanIN and PDAC (p < 0.001), and normal pancreatic duct and high-grade PanIN (p = 0.003). However, no significant differences in the mean H-scores of HIPK2 between low-grade PanIN and high-grade PanIN (p = 0.077), high-grade PanIN and PDAC (p = 0.213), and normal pancreatic duct and low-grade PanIN (p = 0.064) were observed. Among the patients with PDAC, 18 (20%) had low HIPK2 expression, while 72 (80%) had high HIPK2 expression. There was a weak inverse correlation between the H-score of immunohistochemistry of HIPK2 and the H-score of ISH of miR-4653-3p in PDAC (r = −0.218, p = 0.039) (Fig. 6). Low HIPK2 expression was associated with shorter overall and disease-specific survival in the log-rank test. The median overall survival was 16 months (95% CI: 1.448–30.552) for patients with low HIPK2 expression and 29 months (95% CI: 18.209–39.791) for patients with high HIPK2 expression (log-rank test: p = 0.032, Fig. 3b). The median disease-specific survival was 16 months (95% CI: 1.448–30.552) for patients with low HIPK2 expression and 29 months (95% CI: 19.118–38.882) for patients with high HIPK2 expression (log-rank test: p = 0.021, Fig. 3d). However, multivariate analysis showed that miR-HIPK2 was not an independent prognostic factor (Supplementary Table 1b). There was no significant difference in progression-free survival between low and high HIPK2 expression groups (log-rank test: p = 0.687, Fig. 3f). There were no associations with other clinicopathological factors, except for overall and disease-specific survival (Supplementary Table 3).

Discussion
In this study, we used ISH to evaluate the miR-4653-3p expression in patients with PDAC and its correlation with clinicopathological factors. High miR-4653-3p expression significantly correlated with advanced pT, lymph node metastasis, advanced UICC stage, perineural invasion, venous involvement, and shorter overall and disease-specific survival. In addition, miR-4653-3p was not expressed in normal pancreatic ducts, and its expression increased in the order—normal pancreatic duct < low-grade PanIN < high-grade PanIN < PDAC. These results suggest that miR-4653-3p is involved in the early stages of PDAC tumorigenesis in the normal pancreatic duct, low-grade PanIN, and high-grade PanIN. Furthermore, miR-4653-3p reduced HIPK2 expression in vitro, and miR-4653-3p expression inversely correlated with HIPK2 expression in vivo. Unlike that of miR-4653-3p, HIPK2 expression decreased gradually in the order—normal pancreatic duct, low-grade PanIN, high-grade PanIN, and
PDAC. In addition, low HIPK2 expression was associated with shorter and disease-specific survival in patients with PDAC. These results indicate that miR-4653-3p is associated with tumorigenesis and a shorter prognosis, partly by reducing HIPK2 expression.

HIPK2 is a nuclear serine/threonine kinase that represses the transcription of homeodomain-containing transcription factors\(^1\). Its expression and role have been reported in a variety of tumors. HIPK2 is downregulated in tumor cells compared with normal tissues in hepatocellular carcinoma\(^2\), esophageal squamous cell carcinoma\(^3\), urinary bladder cancer\(^4\), colorectal cancer\(^5\), and pancreatic cancer\(^6\). In these tumors, the downregulation of HIPK2 was associated with poor prognosis, promoted migration, tumor growth, metastasis, or increased cell viability\(^2-6\). In contrast, HIPK2 expression was upregulated in tumor cells in tonsillar squamous cell carcinoma\(^7\) and cervical cancer\(^8\). In tonsillar squamous cell carcinoma, HIPK2 overexpression was associated with shorter overall survival and disease-free survival\(^8\). The expression and role of HIPK2 may differ depending on tumor site and histological type.

The expression of HIPK2 in pancreatic tissues, PanIN, and PDAC has been reported in several studies. Qin et al. reported higher HIPK2 expression in adjacent normal pancreatic tissue compared with that in pancreatic cancer tissue, and low HIPK2 expression was associated with poor prognosis\(^9\). Valente et al. reported that HIPK2 expression was significantly lower in PanIN-3 (currently classified as high-grade PanIN) and PDAC than in normal tissues\(^10\). These reports and our results of HIPK2 expression support the notion that HIPK2 downregulation may be associated with the tumorigenesis of PDAC.

We hypothesize that the association between HIPK2 and p53 may also play an important role in the prognosis of pancreatic cancer. The tumor suppressor p53 interacts with HIPK2. HIPK2-mediated phosphorylation of p53 at Ser46 enhances p53-induced apoptosis\(^11\). HIPK2 may stabilize p53 by downregulating p53-induced Mdm2 protein. p53 is one of the major genes associated with tumorigenesis and prognosis of PDAC\(^12\). Therefore, downregulation of HIPK2 in pancreatic cancer leads to the downregulation of p53-associated tumor suppressors, resulting in tumorigenesis and poor prognosis. The inactivation of p53 occurs late in the development of pancreatic neoplasia, for example, in high-grade PanIN and PDAC, but not in low-grade PanIN\(^13\). Based on our results and the HIPK2 expression pattern reported previously, we hypothesized that HIPK2 might be associated with the late stage of PDAC tumorigenesis, which involves p53. In contrast, miR-4653-3p expression was significantly higher in the normal pancreatic duct than in low-grade PanIN. These results indicate that other molecules, besides HIPK2, are controlled by miR-4653-3p and are associated with PDAC tumorigenesis.
In conclusion, this study shows that miR-4653-3p might promote the tumorigenesis and invasiveness of PDAC, in part by inhibiting the expression of HIPK2. ISH of miR-4653-3p may prove useful in predicting tumor invasiveness and prognosis of PDAC. However, more complex molecular mechanisms and other target molecules may also be associated with PDAC tumorigenesis. Thus, further studies are warranted to clarify the association between target molecules and miR-4653-3p in PDAC tumorigenesis.

**Figure 3.** Survival analysis of patients with pancreatic ductal adenocarcinoma in relation to the expression of miR-4653-3p and HIPK2. High miR-4653-3p expression was associated with shorter overall (a) and disease-specific survival (c). In contrast, low HIPK2 expression was associated with shorter overall (b) and disease-specific survival (d). There was no significant difference in the association between progression-free survival and the expression of miR-4653-3p (e) and HIPK2 (f).
Materials and methods

Case selection. Ninety PDAC cases were examined. All patients were diagnosed and treated at Tokai University Hospital (Kanagawa, Japan) between March 2000 and October 2013. Patients who underwent preoperative chemotherapy were excluded from the study. Formalin-fixed and paraffin-embedded (FFPE) tissue samples were cut into 4 μm-thick sections and stained with hematoxylin and eosin (H&E). The H&E-stained sections, pathology reports, and patient medical records were reviewed to confirm PDAC diagnosis and to establish the clinicopathological factors of the patients, including age, sex, tumor size, histological grade, lymph node metastasis, distant metastasis, tumor stage, perineural invasion, lymphatic involvement, venous involvement, and overall survival. Pathological tumor, node, and metastasis (pTNM) staging and histological grade were classified as outlined in the Union for International Cancer Control, 8th edition36. Overall survival was defined as the time interval between surgery and death or the date of the last patient visit. In addition, 30 normal pancreatic ducts, 30 low-grade PanINs, and 30 high-grade PanINs among the PDAC specimens were also examined.

Figure 4. Luciferase reporter assay, RT-qPCR, and western blot analysis. Luciferase reporter assay showed that the miR-4653-3p mimic downregulated luciferase activity on miR-4653-3p target positions compared with the negative control (NC) mimic (a). In real-time RT-qPCR (b), the expression of HIPK2 mRNA in PDAC cells transfected with miR-4653-3p mimic was downregulated compared with the expression in NC cells. In contrast, there was no significant difference in HIPK2 mRNA expression between PDAC cells transfected with miR-4653-3p inhibitor and NC cells. In the western blot analysis (c, d), the expression of HIPK2 in PDAC cells transfected with the miR-4653-3p mimic was downregulated compared with that in NC cells. In contrast, there was no significant difference in HIPK2 mRNA expression between PDAC cells transfected with miR-4653-3p inhibitor and NC cells. Figure 4c shows the HIPK2 and β-actin areas cut out from the original gel image for clarity. Original chemiluminescent image of the capillary and charge data in the western blot analysis are presented in Supplementary Fig. 2. *p < 0.05.
ISH of miR-4653-3p. ISH was performed on 4 μm-thick sections of FFPE tissues obtained from PDAC patients. Sections were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol diluted in PBS. The slides were incubated in proteinase K solution (15 μg/mL) at 37 °C for 10 min and then washed with PBS. A hybridization mix containing digoxigenin-labeled LNA™ microRNA probe (5′DigN/TCTCCAAGCAAC CCTTAACTCCA/3′DigN, final concentration: 5 nM, EXIQON, Woburn, MA, USA) was applied to the sections and hybridization was allowed to occur at 54 °C for 60 min. Thereafter, slides were washed with SSC buffer and incubated with a blocking solution (2% normal sheep serum/PBS, 0.1% Tween20, 1% BSA) for 15 min in a humidified chamber. The blocking solution was removed, anti-DIG reagent, polyclonal sheep anti-DIG-AP diluted 1:800 with antibody diluent (Roche Diagnostics, Mannheim, Germany) were applied, and the sections incubated for 60 min at room temperature. After washing with PBS-T, the cells were incubated with AP substrate (NBT-BCIP (DAKO, Carpinteria, CA, USA) + 0.2 mM levamisole) for 2 h at 30 °C in a humidified chamber.

Figure 5. Immunohistochemical analysis of HIPK2 expression. HIPK2 was expressed in nuclei in pancreatic ducts, acinar cells, and islet cells in normal pancreatic tissue (a) and in low-grade PanIN (b). In high-grade PanIN (c) and PDAC (d), HIPK2 was focally negative or weakly expressed.

Figure 6. Correlation between HIPK2 and miR-4653-3p expression. There was a weak inverse correlation between the H-score of immunohistochemistry of HIPK2 and the H-score of in situ hybridization of miR-4653-3p in PDAC (r = −0.218, p = 0.039).
Slides were incubated twice for 5 min in KTBT buffer to stop the reaction and then washed with water before applying Nuclear Fast Red™ (ScyTek, Logan, UT, USA) for 2 min for nuclear counterstaining. Finally, the slides were washed with water and dehydrated in an ethanol solution.

**Cell culture.** The pancreatic adenocarcinoma cell line, MIA PaCa-2, was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) containing 10% fetal bovine serum and then incubated at 37 °C in a humidified atmosphere containing 5% CO2.

**Transfection of miRNA mimic and inhibitor.** miRIDIAN miRNA mimic and hairpin inhibitor (Dharmacon, Lafayette, CO, USA) of miR-4653-3p were transfected into MIA PaCa-2 cells using DharmaFECT 2 Transfection Reagent (Dharmacon) according to the manufacturer’s protocols. miRIDIAN miRNA Mimic Negative Control #1 (Dharmacon) and miRIDIAN miRNA Hairpin Inhibitor Negative Control #1 (Dharmacon) were used as miRNA mimic and inhibitor controls, respectively. The final concentration of each miRNA mimic, inhibitor, and negative control was 25 nM.

**mRNA microarray.** Total RNA was extracted from MIA PaCa-2 cells transfected with miR-4653-3p mimic or its negative control using the AllPrep DNA/RNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. RNA samples were sent to Macrogen (Macrogen Japan, Kyoto, Japan) for mRNA microarray analysis using SurePrint G3 Human Gene Expression 8 × 60 K v3 (Agilent, Inc., Santa Clara, CA, USA). Comparative analysis between MIA PaCa-2 cells transfected with miR-4653-3p mimic (n = 4) and MIA PaCa-2 cells transfected with mimic negative control (n = 4) was carried out using an independent t-test. A fold change > 2.0 and p < 0.05 were set as the significance threshold. Data analysis was conducted using R 3.3.3 (www.r-project.org).

**Screening for a miR-4653-3p target molecule.** TargetScan v.7.217 (http://www.targetscan.org/vert_72/) and the Human Protein Atlas v. 19.318 (https://www.proteinatlas.org/) databases were screened to identify the miR-4653-3p target molecule.

**RT-qPCR.** Total RNA was extracted from MIA PaCa-2 cells, 48 h after transfection with miR-4653-3p mimic, miR-4653-3p inhibitor, or each NC using the AllPrep DNA/RNA Mini kit (Qiagen) according to the manufacturer’s protocols. To obtain cDNA from total RNA, reverse transcription was performed using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA) and a thermal cycler (Veriti Thermal Cycler, Thermo Fisher Scientific) under the following conditions: 25 °C for 10 min, 37 °C for 120 min, 85 °C for 5 min, and a cooling step at 4 °C. To analyze HIPK2 expression, quantitative real-time PCR was performed using the TaqMan probe (Hs00179759_m1, Thermo Fisher Scientific), TaqMan Universal PCR Master Mix (Thermo Fisher Scientific), and the Step One Plus system (Thermo Fisher Scientific) under the following conditions: polymerase activation at 95 °C for 10 min, 40 cycles of denaturation at 95 °C for 15 s and annealing/extension at 60 °C for 1 min. All samples (n = 5 in each group) were run in triplicate and normalized to GAPDH (Hs02786624_g1, Thermo Fisher Scientific).

**Western blot analysis.** Western blot analysis was performed using a simple western blot assay (ProteinSimple, Santa Clara, CA, USA). Cultured cells were lysed in cell lysis buffer containing protease inhibitors before sonication. The cell lysates were then centrifuged at 10,000 rpm for 3 min to remove the soluble material. The protein concentration of cell lysates was measured using a DC protein concentration of cell lysates was measured using a DC protein assay (Bio-Rad, Hercules, CA, USA). For the simple western blot assay, cell lysates were diluted to 0.4 μg/μL using 0.1 × sample buffer and 5 × Fluorescent Master Mix. The primary antibodies used were as follows: HIPK2 (ab28507, Abcam, Cambridge, United Kingdom) at 1:4,000 as the internal control. Secondary antibodies were prepared by the manufacturer. The assay was conducted according to the manufacturer’s instructions. The assay plate and capillary cartridge were placed into a simple western machine (WES; Protein Simple). All subsequent separation, immunodetection, and analysis steps were performed automatically on the WES. The Compass software (ProteinSimple) was used to visualize the chemiluminescent image of the capillary, analyze the size or charge data, and process the results. The relative HIPK2 expression peak area was normalized to that of β-actin (n = 3 in each experimental group).

**Luciferase reporter assay.** Approximately 500–700 bp fragments containing the miR-4653-3p target site were PCR-amplified from the 3′-UTR of human HIPK2 mRNA using the following primers: forward primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; forward primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; reverse primer for target position 3′-UTR of human HIPK2 mRNA using the following primers: forward primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttgcttatagttaattctagaaagg-3 ′; reverse primer for target position 5947–5953—5′-gttacatgcctatgttatatc-3 ′; forward primer for target position 7620–7627—5′-tcacagtttgtgtaaga-3 ′; reverse primer for target position 929–935—5′-ttg.
1 × cell culture lysis reagent, as supplied in the Luciferase Assay System (Promega, Madison, WI, USA). Luciferase activity was measured using a GloMax 20/20 luminometer (Promega). Relative translocation repression was normalized to the value of the empty pMIR-REPORT luciferase plasmid.

**Immunohistochemistry.** After the FFPE specimens were cut into 4 μm-thick sections and immunohistochemistry was performed to identify HIPK2 (ab28507, rabbit polyclonal; dilution, 1:200; Abcam) using BOND-MAX (Leica Microsystems, Tokyo, Japan), according to the manufacturer’s instructions. Antigen retrieval was performed by treatment with ER1 for 20 min.

**Interpretation of immunohistochemistry and ISH data.** Expression measured using immunohistochemistry and ISH was evaluated using the histochemical scoring system (H-score). H-score (0–300) was calculated as the sum of the staining intensity (0 = negative, 1 + = weak, 2 + = moderate, and 3 + = strong) multiplied by the percentage of cells (0–100) expressed at each intensity. The H-score was calculated using the formula: H-score = 0 × (percentage of negative cells) + 1 × (percentage of 1 + cells) + 2 × (percentage of 2 + cells) + 3 × (percentage of 3 + cells). The optimal H-score cut-off point was determined as the score with the lowest p-value in the overall Kaplan–Meier survival analysis method and the log-rank test. For the miR4653-3pISH assay, an H-score < 90 was considered low, while an H-score ≥ 90 was considered high. For the HIPK2 immunohistochemistry, an H-score < 180 was considered low, while an H-score ≥ 180 was considered high.

**Statistical analyses.** Statistical analyses were conducted using SPSS v26 (IBM Corp., Armonk, NY, USA). Fisher’s exact test and Pearson’s χ² test were used to analyze the relationship between clinicopathological factors and the expression of miR-4653-3p or HIPK2. Two-sample Student’s t-test or Welch’s t-test was used to compare the expression of HIPK2 or miR-4653-3p as determined with RT-qPCR, western blot, immunohistochemistry, and ISH analyses. The correlation between the expression of miR-4653-3p and HIPK2 was evaluated using Spearman correlation analysis. Survival curves were plotted using the Kaplan–Meier method and compared using a log-rank test. Survival was also evaluated in univariate and multivariate analyses using Cox proportional hazard regression models to identify independent prognostic factors. First, a univariate analysis of overall survival was performed for each clinicopathological factor. Statistically significant factors in the univariate analysis were then included in the multivariable analysis using the forward selection method (likelihood ratio); p < 0.05 was considered statistically significant.

**Ethics approval and consent to participate.** This study was approved by the Research Ethics Committee of Tokai University School of Medicine (No. 17R275) and was performed according to the Declaration of Helsinki. The informed consent was obtained from all subjects through an opt-out methodology.

**Data availability** All data analyzed in this study are included in this published article and its supplementary information files. The datasets of gene expression generated and/or analyzed during the current study are available in the ArrayExpress repository, ArrayExpress accession E-MTAB-11813.

Received: 14 May 2022; Accepted: 21 October 2022

Published online: 26 October 2022

**References**

1. Hidalgo, M. et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. *Pancreatology* **15**, 8–18 (2015).
2. Hruban, R. H. et al. A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. *Am. J. Surg Pathol.* **39**, 1730–1741 (2015).
3. Hruban, R. H. et al. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. *Am. J. Surg. Pathol.* **25**, 579–586 (2001).
4. WHO Classification of Tumours Digestive System Tumors. 5th ed. Lyon, France: International Agency for Research on Cancer (IARC) (2019).
5. D’Angelo, B., Benedetti, E., Cimini, A. & Giordano, A. MicroRNAs: A puzzling tool in cancer diagnostics and therapy. *Anticancer Res.* **36**, 5571–5575 (2016).
6. Abreu, F. R., Liu, X. & Tsongalis, G. J. miRNA analysis in pancreatic cancer: The Dartmouth experience. *Clin. Chem. Lab. Med.* **55**, 755–762 (2017).
7. Khan, S., Ansarullah, A., Kumar, D., Jaggi, M. & Chauhan, S. C. Targeting microRNAs in pancreatic cancer: microplayers in the big game. *Cancer Res.* **73**, 6541–6547 (2013).
8. Huang, J. et al. Advance in microRNA as a potential biomarker for early detection of pancreatic cancer. *Biomark. Res.* **4**, 20 (2016).
9. Yu, S. et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. *Cancer Res.* **70**, 6015–6025 (2010).
10. Xue, Y. et al. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm. *Cancer Genet.* **206**, 217–221 (2013).
11. Khan, S. et al. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. *Oncotarget* **5**, 7599–7609 (2014).
12. Chen, P.-H. et al. The miR-204-3p-targeted IGFBP2 pathway is involved in xanthohumol-induced glioma cell apoptotic death. *Neuropharmacology* **110**, 362–375 (2016).
13. Liu, S. et al. Regulatory roles of miRNA in the human neural stem cell transformation to glioma stem cells. *J. Cell. Biochem.* **115**, 1368–1380 (2014).
14. Wang, X. et al. Differential expression profile analysis of miRNAs with HER-2 overexpression and intervention in breast cancer cells. *Int. J. Clin. Exp. Pathol.* **10**, 5039–5062 (2017).
15. Peng, X. et al. MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo. Int. J. Clin. Exp. Pathol. 7, 6784 (2014).

16. Zhong, X. et al. MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy. Oncotarget 7, 61166–61182 (2016).

17. Agarwal, V., Bell, G.W., Nam, J.W. & Bartel, D.P. Predicting effective microRNA target sites in mammalian mRNAs. eLife 4, e05005 (2015).

18. Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Science 357, 6352 (2017).

19. Wang, Y., Debatin, K. M. & Hug, H. HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels. BMC Mol. Biol. 2, 8 (2001).

20. Chen, P. et al. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1alpha. Oncogene 39, 2863–2876 (2020).

21. Zhang, Z. et al. HIPK2 inhibits cell metastasis and improves chemosensitivity in esophageal squamous cell carcinoma. Exp. Ther. Med. 15, 1113–1118 (2018).

22. Tan, M. et al. Downregulation of homeodomain-interacting protein kinase-2 contributes to bladder cancer metastasis by regulating Wnt signaling. J. Cell. Biochem. 115, 1762–1767 (2014).

23. Zhou, L. et al. Verbacoside promotes apoptosis by regulating HIPK2-p53 signaling in human colorectal cancer. BMC Cancer 14, 747 (2014).

24. Qin, Y. et al. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/c-Myc axis in pancreatic cancer. Cell Prolif. 52, e12603 (2019).

25. Lin, J. et al. Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating Wip1. PLoS ONE 9, e98418 (2014).

26. Soubeyran, J. et al. Tissue microarray cytometry reveals positive impact of homeodomain interacting protein kinase 2 in colon cancer survival irrespective of p53 function. Am. J. Pathol. 178, 1986–1998 (2011).

27. Kwon, M. J., Kang, S. Y., Nam, E. S., Cho, S. J. & Rho, Y. S. HIPK2 overexpression and its prognostic role in human papillomavirus-positive tonsillar squamous cell carcinoma. Biomed. Res. Int. 2017, 1056427 (2017).

28. Cheng, Y. et al. Correlation between homeodomain-interacting protein kinase 2 and apoptosis in cervical cancer. Mol. Med. Rep. 5, 1251–1255 (2012).

29. Al-Beiti, M. A. & Lu, X. Expression of HIPK2 in cervical cancer: correlation with clinicopathology and prognosis. Aust. N. Z. J. Obstet. Gynaecol. 48, 329–336 (2008).

30. Valente, D. et al. HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. Oncotarget 6, 10320–10334 (2015).

31. Crone, J. et al. Zyxin is a critical regulator of the apoptotic HIPK2-p53 signaling axis. Cancer Res. 71, 2350–2359 (2011).

32. Hofmann, T. G. et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4, 1–10 (2002).

33. Oshima, M. et al. Immuno histochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann. Surg. 258, 336–346 (2013).

34. Hruby, R. H., Goggins, M., Parsons, J. & Kern, S. E. Progression model for pancreatic cancer. Clin. Cancer Res. 6, 2969–2972 (2000).

35. Brierley, J., Gospodarowicz, M. & Wittekind, C. UICC TNM Classification of Malignant Tumours. 8th ed. Hoboken (New Jersey: Wiley Blackwell, 2017).

36. Lee, H. J. et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 68, 375–382 (2010).

Acknowledgements
The authors would like to thank Ms. Ayako Kawase and Mr. Hirotaka Kono, all the technicians in the Division of Diagnostic Pathology, Tokai University Hospital, and Ms. Ayumi Sasaki in the Support Center for Medical Research and Education, Tokai University, for their valuable technical assistance. We would like to thank Editage (www.editage.com) for English language editing.

Author contributions
K.H. designed and performed the experiments, analyzed the data, and wrote the manuscript. M.Mi., Y.T., and T.S. performed the experiments and analyzed the data. A.K. and M.Mo. summarized clinicopathological data. T.N. provided the materials. N.N. reviewed the manuscript. All authors were involved in writing the paper and had final approval of the submitted and published versions.

Funding
This study was supported by the Research and Study Project of the Tokai University Educational System's General Research Organization Grant Number PJ2014–06 and JSPS KAKENHI Grant Number JP16K08659, JP19K07470.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-22950-2.

Correspondence and requests for materials should be addressed to K.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
